Evidence map›Paper›PMID 24831003›Full record

ArticleThe Journal of biological chemistry2014

Identification of mixed lineage leukemia 1(MLL1) protein as a coactivator of heat shock factor 1(HSF1) protein in response to heat shock protein 90 (HSP90) inhibition.

Yaoyu Chen, Jinyun Chen, Jianjun Yu, Guizhi Yang, Emilia Temple, Fred Harbinski, Hui Gao, Christopher Wilson, Raymond Pagliarini, Wenlai Zhou

Open access · hybridAbstract read
In one paragraph

Article in The Journal of biological chemistry, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.7field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Yaoyu ChenFrom the Departments of Oncology.
Jinyun ChenFrom the Departments of Oncology.
Jianjun Yuthe Department of Oncology, Novartis Institutes for Biomedical Research, Emeryville, California 94608.
Guizhi YangFrom the Departments of Oncology.
Emilia TempleDevelopmental and Molecular Pathways, and.
Fred HarbinskiDevelopmental and Molecular Pathways, and.
Hui GaoFrom the Departments of Oncology.
Christopher WilsonNeuroscience, Novartis Institutes for Biomedical Research, Cambridge, Massachusetts 02139 and.
Raymond PagliariniFrom the Departments of Oncology.
Wenlai ZhouFrom the Departments of Oncology, wenlai.zhou@novartis.com.
Novartis (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Heat shock protein 90 (HSP90) inhibition inhibits cancer cell proliferation through depleting client oncoproteins and shutting down multiple oncogenic pathways. Therefore, it is an attractive strategy for targeting human cancers. Several HSP90 inhibitors, including AUY922 and STA9090, show promising effects in clinical trials. However, the efficacy of HSP90 inhibitors may be limited by heat shock factor 1 (HSF1)-mediated feedback mechanisms. Here, we identify, through an siRNA screen, that the histone H3 lysine 4 methyltransferase MLL1 functions as a coactivator of HSF1 in response to HSP90 inhibition. MLL1 is recruited to the promoters of HSF1 target genes and regulates their expression in response to HSP90 inhibition. In addition, a striking combination effect is observed when MLL1 depletion is combined with HSP90 inhibition in various human cancer cell lines and tumor models. Thus, targeting MLL1 may block a HSF1-mediated feedback mechanism induced by HSP90 inhibition and provide a new avenue to enhance HSP90 inhibitor activity in human cancers.

Indexed as

AnimalsCell LineDNA-Binding ProteinsGene Expression RegulationGene Knockdown TechniquesHeat Shock Transcription FactorsHistone-Lysine N-MethyltransferaseHSP90 Heat-Shock ProteinsHumansIsoxazolesMiceMyeloid-Lymphoid Leukemia ProteinPromoter Regions, GeneticResorcinolsRNA, Small InterferingTranscription Factors5-(2,4-dihydroxy-5-isopropylphenyl)-4-(4-morpholin-4-ylmethylphenyl)isoxazole-3-carboxylic acid ethylamideDNA-Binding ProteinsHeat Shock Transcription FactorsHistone-Lysine N-MethyltransferaseHSF1 protein, humanHsf1 protein, mouseHSP90 Heat-Shock ProteinsIsoxazolesKMT2A protein, humanKmt2a protein, mouseMyeloid-Lymphoid Leukemia ProteinResorcinolsRNA, Small InterferingTranscription FactorsAnticancer DrugHeat Shock Factor 1 (HSF1)Heat Shock Protein 90 (HSP90)Tumor Cell BiologyTumor Therapy

Identifiers

PMID24831003
PMCPMC4081932
OpenAlexW2040214100

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.